Cardiovascular Systems, Inc. Appoints Jeffery W. Chambers, M.D., as Chief Medical Officer
March 04 2022 - 7:00AM
Business Wire
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical
device company developing and commercializing innovative
interventional treatment systems for peripheral and coronary
vascular disease, today announced that it has appointed Jeffery W.
Chambers, M.D., as Chief Medical Officer.
“CSI is developing an exciting product pipeline that targets
some of the fastest growing segments of interventional cardiology,”
said Scott Ward, Chairman, President and Chief Executive Officer.
“Jeff brings contemporary interventional cardiology practice and
extensive clinical research experience to CSI as we seek to expand
our product offering beyond orbital atherectomy. We believe Jeff
brings valuable perspective to CSI as we seek to successfully
develop and commercialize everolimus drug coated balloons,
intravascular lithotripsy balloons, thrombectomy devices and
mechanical circulatory support products.”
Said Chambers, “I am excited to join CSI and I look forward to
working with the team to bring innovative and important
technologies to underserved patient populations. In doing so,
together, we will improve the health of people with coronary and
peripheral artery disease and fulfill our Mission.”
Dr. Chambers was the primary investigator for the ORBIT II
study, which served as the pivotal trial supporting the premarket
approval for the use of orbital atherectomy in coronary arteries.
In addition, he has served as a consultant in connection with CSI’s
product development, quality assurance, medical affairs and
clinical research.
Dr. Chambers received his medical degree from Wayne State
University and completed his residency in Internal Medicine and
fellowships in cardiovascular disease and interventional cardiology
at the University of Minnesota. He has been employed at the
Metropolitan Heart and Vascular Institute since 1995. Dr. Chambers
is a serial entrepreneur with numerous issued patents, some of
which are associated with devices commercially available today. He
is a Fellow at The American College of Cardiology and is a member
of The Society for Cardiovascular Angiography and
Interventions.
About Cardiovascular Systems, Inc. Cardiovascular
Systems, Inc., based in St. Paul, Minn., is a medical device
company focused on developing and commercializing innovative
solutions for treating peripheral and coronary vascular disease.
The company’s orbital atherectomy system treats calcified and
fibrotic plaque in arterial vessels throughout the leg and heart
and addresses many of the limitations associated with existing
surgical, catheter and pharmacological treatment alternatives. For
additional information, please visit www.csi360.com and connect on
Twitter @csi360.
Safe Harbor Certain statements in this news release are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 and are provided under the
protection of the safe harbor for forward-looking statements
provided by that Act. For example, statements in this press release
regarding the expansion of CSI’s product offering and the benefits
to CSI thereof, are forward-looking statements. These statements
involve risks and uncertainties that could cause results to differ
materially from those projected, including, but not limited to,
successful the development of new devices; agreements with
development partners, advisors and other third parties; the ability
of CSI and these third parties to meet development, contractual and
other milestones; contractual rights and obligations; technical
challenges; satisfaction of milestones and conditions to CSI’s
rights to acquire new devices; regulatory developments; clinical
trial requirements and results; FDA requirements, clearances and
approvals; the experience of physicians regarding the effectiveness
and reliability of products sold by CSI; the reluctance of
physicians, hospitals and other organizations to accept new
products; the impact of competitive products and pricing;
intellectual property protections; general economic conditions; and
other factors detailed from time to time in CSI’s SEC reports,
including its most recent annual report on Form 10-K and subsequent
quarterly reports on Form 10-Q. CSI encourages you to consider all
of these risks, uncertainties and other factors carefully in
evaluating the forward-looking statements contained in this
release. As a result of these matters, changes in facts,
assumptions not being realized or other circumstances, CSI's actual
results may differ materially from the expected results discussed
in the forward-looking statements contained in this release. The
forward-looking statements made in this release are made only as of
the date of this release, and CSI undertakes no obligation to
update them to reflect subsequent events or circumstances.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220302005944/en/
Cardiovascular Systems, Inc. Jack Nielsen Vice President,
Investor Relations & Corporate Communications (651) 202-4919
j.nielsen@csi360.com
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jul 2023 to Jul 2024